NDC product
Imatinib Mesylate
NDC 0378-2245 · Mylan Pharmaceuticals Inc.
Key facts
| Product NDC | 0378-2245 |
|---|---|
| Proprietary name | Imatinib Mesylate |
| Nonproprietary name | imatinib |
| Substances | IMATINIB MESYLATE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Mylan Pharmaceuticals Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA204644 |
| Pharmacologic classes | Bcr-Abl Tyrosine Kinase Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC] |
| Marketing start | Sep 28, 2017 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: